{"pmcid": 4678179, "prompt_strategy": "zeroshot", "model": "gpt-5.1", "extractions": [{"outcome": "progression-free-survival (PFS)", "intervention": "vismodegib plus gemcitabine (GV)", "comparator": "gemcitabine plus placebo (GP)", "intervention_group_size": 53, "comparator_group_size": 53, "intervention_mean": 4.0, "comparator_mean": 2.5, "pmcid": "PMC4696034", "outcome_type": "continuous"}, {"outcome": "Median overall survival (OS)", "intervention": "vismodegib plus gemcitabine (GV)", "comparator": "gemcitabine plus placebo (GP)", "intervention_group_size": 53, "comparator_group_size": 53, "intervention_mean": 6.9, "comparator_mean": 6.1, "pmcid": "PMC4696034", "outcome_type": "continuous"}, {"outcome": "Response rates", "intervention": "vismodegib plus gemcitabine (GV)", "comparator": "gemcitabine plus placebo (GP)", "intervention_group_size": 53, "comparator_group_size": 53, "intervention_events": 4, "comparator_events": 7, "pmcid": "PMC4696034", "outcome_type": "binary"}, {"outcome": "rate of adverse events", "intervention": "vismodegib plus gemcitabine (GV)", "comparator": "gemcitabine plus placebo (GP)", "intervention_group_size": 53, "comparator_group_size": 53, "pmcid": "PMC4696034", "outcome_type": "binary"}], "errors": []}
